SI20849A - Tekoči sestavki za oralno uporabo - Google Patents

Tekoči sestavki za oralno uporabo Download PDF

Info

Publication number
SI20849A
SI20849A SI200020031A SI200020031A SI20849A SI 20849 A SI20849 A SI 20849A SI 200020031 A SI200020031 A SI 200020031A SI 200020031 A SI200020031 A SI 200020031A SI 20849 A SI20849 A SI 20849A
Authority
SI
Slovenia
Prior art keywords
pharmaceutical composition
composition according
acid
percent
group
Prior art date
Application number
SI200020031A
Other languages
English (en)
Slovenian (sl)
Inventor
Edward S. Wilson
Laura A. Trespidi
Christy M. Clark
Ashok J. Desai
Glenn A. Meyer
Frederick D. Sancilio
Original Assignee
Aaipharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23395748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI20849(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aaipharma Inc. filed Critical Aaipharma Inc.
Publication of SI20849A publication Critical patent/SI20849A/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200020031A 1999-07-16 2000-07-14 Tekoči sestavki za oralno uporabo SI20849A (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/354,982 US6365180B1 (en) 1998-01-20 1999-07-16 Oral liquid compositions
PCT/US2000/019372 WO2001013897A1 (en) 1999-07-16 2000-07-14 Oral liquid compositions

Publications (1)

Publication Number Publication Date
SI20849A true SI20849A (sl) 2002-10-31

Family

ID=23395748

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200020031A SI20849A (sl) 1999-07-16 2000-07-14 Tekoči sestavki za oralno uporabo

Country Status (18)

Country Link
US (1) US6365180B1 (xx)
EP (1) EP1196147A4 (xx)
JP (1) JP2003507415A (xx)
KR (1) KR20020050223A (xx)
CN (1) CN1407887A (xx)
AU (1) AU770772B2 (xx)
BR (1) BR0012488A (xx)
CA (1) CA2376180A1 (xx)
CZ (1) CZ2002129A3 (xx)
HR (1) HRP20020045A2 (xx)
MX (1) MXPA02000583A (xx)
NO (1) NO20020208L (xx)
RU (1) RU2252019C2 (xx)
SI (1) SI20849A (xx)
SK (1) SK572002A3 (xx)
UA (1) UA80085C2 (xx)
WO (1) WO2001013897A1 (xx)
ZA (1) ZA200200741B (xx)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602467B1 (en) * 1998-07-24 2003-08-05 Therox, Inc. Apparatus and method for blood oxygenation
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
JP4865958B2 (ja) * 2001-05-23 2012-02-01 株式会社トクホン 鎮痛抗炎症局所作用型の貼付剤
US7855082B1 (en) 2001-10-31 2010-12-21 Astrazeneca Ab Raman spectroscopic method for determining the ratio of 5-methoxy and 6-methoxy isomers of omeprazole
US20040006109A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of non-enterically coated acid-labile drugs
AU2003278935A1 (en) * 2002-09-26 2004-04-19 Myriad Genetics, Inc Method and composition for treating neurodegenerative disorders
ITMI20022777A1 (it) * 2002-12-27 2004-06-28 Altergon Sa Formulazioni farmaceutiche per ormoni tiroidei e procedimenti per il loro ottenimento.
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
JP2007528857A (ja) * 2003-07-11 2007-10-18 ミリアド ジェネティクス， インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
EP1648417A4 (en) * 2003-07-18 2010-01-20 Santarus Inc PHARMACEUTICAL FORMULATION AND METHOD FOR THE TREATMENT OF GASTROINTESTINAL ACIDITY RELATED DISORDERS
AR045062A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
EP1718303A4 (en) * 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
US20050203115A1 (en) * 2004-03-10 2005-09-15 Sancilio Frederick D. Narcotic-NSAID ion pairs
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
MXPA06011820A (es) * 2004-04-16 2006-12-15 Santarus Inc Combinacion de inhibidor de bomba de proton, agente regulador del ph y agente procinetico.
KR20070004036A (ko) * 2004-04-29 2007-01-05 키스톤 리테이닝 월 시스템스, 아이엔씨 벽, 옹벽 및 그 외 유사한 것을 위한 베니어
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ITMI20041245A1 (it) * 2004-06-22 2004-09-22 Ibsa Inst Biochimique Sa Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US20060088590A1 (en) * 2004-10-22 2006-04-27 Banner Pharmacaps, Inc. Non-blooming gelatin and non-gelatin formulations
US20060105045A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
US20060105992A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
US20070053868A1 (en) 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
EP1903039A4 (en) * 2005-06-13 2010-09-22 Takeda Pharmaceutical INJECTION
WO2006138534A2 (en) * 2005-06-15 2006-12-28 Morton Grove Pharmaceuticals, Inc. Stable warfarin sodium liquid formulation and method of making same
JO3352B1 (ar) * 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
US20070148238A1 (en) * 2005-06-23 2007-06-28 Spherics, Inc. Dosage forms for movement disorder treatment
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
US8333989B2 (en) * 2005-10-26 2012-12-18 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
US20070232567A1 (en) * 2006-03-28 2007-10-04 Curtis Wright Formulations Of Low Dose Non-Steroidal Anti-Inflammatory Drugs And Beta-Cyclodextrin
KR20150050595A (ko) * 2006-03-28 2015-05-08 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
CA2673511A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
NZ579972A (en) * 2007-05-24 2012-03-30 Novartis Ag Oral dosage form of diclofenac providing fast absorption of drug
US7662858B2 (en) 2008-05-23 2010-02-16 Aaipharma, Inc. Method of treating post-surgical acute pain
KR101096429B1 (ko) * 2008-07-18 2011-12-20 한국유나이티드제약 주식회사 안정성이 향상된 아세클로페낙의 경구용 연질캅셀제
US8435562B2 (en) * 2009-11-09 2013-05-07 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
KR101346750B1 (ko) * 2010-06-07 2013-12-31 한국콜마주식회사 나프록센 액상 조성물을 함유하는 밀봉된 경질캡슐제
GB201021267D0 (en) * 2010-12-15 2011-01-26 Reckitt Benckiser Healthcare Int Ltd Novel pharmaceutical formulation
AU2012286596B2 (en) * 2011-07-27 2015-08-20 B Athanassiadis Dental Pty Ltd Alkaline compositions and their dental and medical use
CA2852447A1 (en) 2011-10-19 2013-04-25 R.P. Scherer Technologies, Llc Two phase pharmaceutical delivery system
US20150250750A1 (en) 2012-10-16 2015-09-10 Wockhardt Limited Pharmaceutical compostions of diclofenac or salts thereof
US20150250751A1 (en) 2012-10-16 2015-09-10 Wockhardt Limited Pharmaceutical compositions of diclofenac or salts thereof
WO2014060857A1 (en) 2012-10-19 2014-04-24 Wockhardt Limited Pharmaceutical compositions of diclofenac or salts thereof
ES2792682T3 (es) 2014-02-10 2020-11-11 Respivant Sciences Gmbh Métodos para el tratamiento de enfermedades pulmonares con estabilizadores de mastocitos
PT3104853T (pt) 2014-02-10 2020-01-14 Respivant Sciences Gmbh Tratamento com estabilizadores de mastócitos para distúrbios sistémicos
PL3209302T3 (pl) 2014-10-21 2019-10-31 Abbvie Inc Proleki karbidopy i L-dopy oraz ich zastosowanie do leczenia choroby Parkinsona
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017027387A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
AU2017321495A1 (en) 2016-08-31 2019-03-21 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
JP2019531308A (ja) 2016-10-07 2019-10-31 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 肺線維症の治療のためのクロモリン組成物
IT201700015145A1 (it) * 2017-02-10 2018-08-10 Altergon Sa Capsule di gelatina molle ad elevata stabilità
GB2585628A (en) * 2019-05-08 2021-01-20 Alkaloid Ad Pharmaceutical formulation
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
WO2023235541A1 (en) * 2022-06-03 2023-12-07 Polaryx Therapeutics, Inc. Gemfibrozil formulation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4028772A (en) 1971-04-02 1973-09-27 Merck & Co., Inc Chemical processes
HU185926B (en) 1979-09-27 1985-04-28 Agostne Kahan Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
US4880835A (en) 1988-11-03 1989-11-14 Formulations Development Labs, Inc. Oral liquid pharmaceutical compositions of sulindac
JPH0717498B2 (ja) * 1989-05-31 1995-03-01 興和株式会社 鎮咳去痰ソフトカプセル剤
CA2017916C (en) 1989-06-07 1999-02-02 Minoru Aoki Etoposide preparations
US5024997A (en) * 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
US5141961A (en) * 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives
US5183829A (en) * 1991-09-27 1993-02-02 Applied Analytical Industries, Inc. Oral liquid compositions of non-steroidal anti-inflammatory drugs
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
US5505961A (en) 1993-08-05 1996-04-09 R. P. Scherer Corporation Gelatin capsules containing a highly concentrated acetaminophen solution
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
PL315635A1 (en) * 1994-01-24 1996-11-25 Procter & Gamble Method of solubilising hardly pharmaceutically active substances
ES2088742B1 (es) * 1994-06-29 1997-03-16 Salvat Lab Sa Composicion antibiotica de aplicacion otica.
CA2141126A1 (en) * 1995-01-26 1996-07-27 Natalie J. Lazarowych Combinational drug for treating migraine and other illnesses
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US5516789A (en) * 1995-04-12 1996-05-14 Abbott Laboratories Lipoxygenase and cyclooxygenase inhibiting compounds
US6013280A (en) 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
IT1295369B1 (it) * 1997-10-21 1999-05-12 Fatro Spa Composizione a base di tiamfenicolo e diclofenac
ATE429210T1 (de) * 1998-01-20 2009-05-15 Applied Analytical Ind Inc Orale flüssige zusammensetzungen

Also Published As

Publication number Publication date
UA80085C2 (en) 2007-08-27
RU2252019C2 (ru) 2005-05-20
CA2376180A1 (en) 2001-03-01
NO20020208D0 (no) 2002-01-15
WO2001013897A1 (en) 2001-03-01
SK572002A3 (en) 2002-08-06
ZA200200741B (en) 2003-06-25
HRP20020045A2 (en) 2006-06-30
JP2003507415A (ja) 2003-02-25
CZ2002129A3 (cs) 2002-08-14
AU770772B2 (en) 2004-03-04
AU6216800A (en) 2001-03-19
NO20020208L (no) 2002-03-18
EP1196147A1 (en) 2002-04-17
CN1407887A (zh) 2003-04-02
KR20020050223A (ko) 2002-06-26
MXPA02000583A (es) 2003-10-14
US6365180B1 (en) 2002-04-02
EP1196147A4 (en) 2005-04-20
BR0012488A (pt) 2002-04-02

Similar Documents

Publication Publication Date Title
SI20849A (sl) Tekoči sestavki za oralno uporabo
CA2318128C (en) Oral liquid compositions
FI85216B (fi) Foerfarande foer farmstaellning av ett oralt administrerbart farmaceutisk preparat av 5-amino-salicylsyra.
JP2000514051A (ja) ベンズイミダゾール誘導体を活性成分とする経口投与用の安定な薬剤形およびその製造方法
ES2584403T3 (es) Procedimiento de elaboración de microcápsulas entéricas de alginato por gelación iónica que contienen diclofenac o una de sus sales y composición farmacéutica multiparticulada que las contiene
EP1711162A1 (fr) Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
PT571973E (pt) Comprimidos de valproato de sodio de libertacao retardada
CA2621545A1 (en) Ramipril formulation
AU2003203901B2 (en) Oral liquid compositions
JP2006514982A (ja) 非ステロイド抗炎症薬投薬計画
WO2007099559A2 (en) Method of preparation for novel composition of 2-{(2,6 dichlorophenyl) amino] benzeneacetic acid carboxymethyl ester or 2-[2-[2-(2,6-dichlorophenyl) amino] phenylacetoxyacetic acid and method of its use
ZA200610513B (en) Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same
Rajeev et al. Formulation of a novel immediate release heterolithic buccal patch of aspirin
EP1242062B1 (en) Anhydrous gel comprising nsaid for topical administration to the oral cavity
JP2004035535A (ja) 非ステロイド系抗炎症薬剤を含む経口医薬組成物及びその製造方法
WO2019098984A1 (en) Synergistic combination of diclofenac, famotidine and a carbonate
JP2005145932A (ja) 消炎鎮痛外用剤
KR100320140B1 (ko) 5-니트로이미다졸유도체의마이크로그래뉼
RU2182016C2 (ru) Спазмолитическая композиция, способ получения спазмолитической композиции
KR100625506B1 (ko) 아세클로페낙과 미소프로스톨의 약제학적 조성물 및 그의제조방법
WO2020131856A1 (en) Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
TR201711764A2 (tr) Ağrı ve enflamasyonun tedavisi için diklofenak ve H2 reseptör antagonistleri.
BRPI0318201B1 (pt) Forma de dosagem de fármaco antiinflamatório não-esteroidal
FR2932387A1 (fr) Composition orale contenant un agent anti-plaqettaire de la famille des thienopyridines sous forme de base.
WO2014060856A1 (en) Pharmaceutical compositions of diclofenac or salts thereof

Legal Events

Date Code Title Description
IF Valid on the event date